News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investing.com - AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, flatly quashing reports of a merger that would have created a pharmaceutical giant worth nearly …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Shares of AstraZeneca PLC (AZN) rose 2.52% to £120.36 on Wednesday, outperforming the FTSE 100 Index, which increased by 0.08%. The company's stock closed 23.49% below its 52-week high of £157.32.
AstraZeneca and Bristol Myers Squibb never held merger discussions and are not in talks now, a senior source close to the matter told Reuters on Wednesday. "There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Brokers split on AstraZeneca merger talk as shares recover some ground Proactive uses images sourced from Shutterstock Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks +14.4%BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).SOPHiA GENETICS Logo This multi-year collaboration agreement will advance …
Sharemaestro market context Price below Trend Line 52 weeks -4.0%AstraZeneca shares dropped significantly due to rumors of a potential mega-merger with Bristol Myers Squibb and a failed late-stage trial for its heart disease program, Wainua. Despite these setbacks, an investor is not selling, viewing the decline as a market overreaction rather than a …
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks +14.4%A recent report indicates that deal talks between AstraZeneca and Bristol-Myers Squibb are still ongoing. Following this news, Bristol-Myers Squibb's shares saw a slight increase, while AstraZeneca's shares experienced a minor decline. This update follows an earlier Financial Times report about potential acquisition discussions.
Morningstar reports on the potential megamerger between Bristol-Myers Squibb and AstraZeneca, noting that such large acquisitions are rare in biopharma. While the deal could combine complementary patent portfolios and pipeline assets, concerns exist regarding integration challenges and regulatory hurdles due to overlapping oncology focuses. …
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company developing cancer, rare-disease and other medicines, plunged approximately 7.7% in Monday's U.S. regular-session trading as investors assessed reported merger discussions with Bristol Myers Squibb (NYSE:BMY), a U.S. biopharmaceutical company. A combination could …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments
Sharemaestro market context Price below Trend Line 52 weeks +14.4%The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%All three major US stock indexes were up in late-morning trading Monday after President Donald Trump PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense. View Comments
Sharemaestro market context Price below Trend Line 52 weeks +14.4%European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca completed a direct listing on the New York Stock Exchange back in February, after delisting its American Depositary Receipts from the Nasdaq Credit: Michael Nagle / Bloomberg via Getty Images Key Takeaways Bristol Myers Squibb shares rose Monday following reports of merger talks …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AIM ImmunoTech Inc. Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the final subject …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca PLC (AZN) shares fell by 8.96% to £115.00 on Monday, underperforming the broader market as the FTSE 100 Index also saw a slight decline. This drop left AstraZeneca's stock 26.90% below its 52-week high achieved in February.
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the UK drugmaker and the country's second most valuable listed company, fell 6.27% in London after news that it has held talks with Bristol Myers Squibb (NYSE:BMY) about a combination valued near $400 billion, according to …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth more than £300 billion, according to reports. The two pharmaceutical firms have held discussions over a potential tie-up in recent months, the Financial Times …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca's shares fell by 7% on news of potential talks to acquire US rival Bristol Myers Squibb, a deal that could create a pharmaceutical giant worth nearly $400 billion. The acquisition would significantly expand AstraZeneca's presence in the US and mark a strategic shift …
Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …
Sharemaestro market context Price below Trend Line 52 weeks -4.0%(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported. Neither company has disclosed any details of the merger, and deal closure timelines are unclear. Both AstraZeneca and Bristol …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report. A combined entity would carry a value of nearly $400 billion, which …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Search by ticker symbol or company name and select a result to open its chart.